Systemic therapy in metastatic renal cell carcinoma

PURPOSE: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunother...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedke, Jens, Gauler, Thomas, Grünwald, Viktor, Hegele, Axel, Herrmann, Edwin, Hinz, Stefan, Janssen, Jan, Schmitz, Stephan, Schostak, Martin, Tesch, Hans, Zastrow, Stefan, Miller, Kurt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272893/
https://www.ncbi.nlm.nih.gov/pubmed/27277600
http://dx.doi.org/10.1007/s00345-016-1868-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272893/
https://www.ncbi.nlm.nih.gov/pubmed/27277600
http://dx.doi.org/10.1007/s00345-016-1868-5

Ejemplares similares